Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027

MT Newswires Live

Sep 10

Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.

Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.

Price: 4.32, Change: -0.03, Percent Change: -0.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2666594628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666594628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666594628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666594628","market":"hk","top_or_hot":-1,"title":"Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027","media":"MT Newswires Live","content":"<html><body><p> Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.</p><p>Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.</p><p>Price: 4.32, Change: -0.03, Percent Change: -0.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-10 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.</p><p>Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.</p><p>Price: 4.32, Change: -0.03, Percent Change: -0.69</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666594628","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666594628","pubTimestamp":1789052267,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optimi Health  plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.Price: 4.32, Change: -0.03, Percent Change: -0.69","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OPTH":"OPTIMI HEALTH CORP."},"translate_title":"Optimi Health 将于 2027 年上半年启动裸盖菇素辅助治疗重度抑郁症的 2 期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPTH":1},"content_text":"Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.Price: 4.32, Change: -0.03, Percent Change: -0.69","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}